PDL goes public with hostile bid to buy Neos

Spotlight
Neos’ board said PDL's previous $10.25-a-share offer “substantially undervalued” the company.

PDL BioPharma has gone public with its attempt to buy Neos Therapeutics. The investment group told the world of its desire to buy the ADHD specialist after twice being rebuffed.

Incline Village, Nevada-based PDL put a $10.25-a-share offer to Neos in June. Days later, Neos carried out a dilutive financing at $6.25 share. That meant, all else being equal, PDL would have to pay more to buy Neos. Despite that, PDL kept its bid at $10.25 a share. Neos’ board recently rejected that second, effectively improved offer.

PDL has now gone public with its plans, a move it says was motivated by Neos’ “board's refusal to negotiate in good faith toward a transaction.” The $10.25-a-share offer represents a 40% premium over Neos’ stock price just before news of PDL’s plans broke. Neos’ stock rose more than 35% on the back of the news, closing just shy of the offer price at $10.05.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

If PDL can complete the deal, it will add two approved drugs and one near-market pipeline prospect to its portfolio. Neos has built its business on extended-release and orally disintegrating tablet technologies. The technologies underpin its approved pediatric formulations of amphetamine and methylphenidate, as well as a second amphetamine formulation that is awaiting approval by the FDA.

RELATED: Neos wins FDA approval for a melts-in-your-mouth take on Adderall for ADHD

PDL’s pitch to Neos is based on a belief that its resources can accelerate adoption of these products and the development of new drugs based on the same technologies. That pitch, and the cash tied to it, failed to woo Neos’ board. The question now is whether dialing up the pressure on Neos will deliver a breakthrough.

The board unanimously rejected both of the earlier offers on the grounds they failed to reflect its “strategic value and future prospects for continued growth and value creation.” Neos’ board is now considering the latest offer. But, given the board felt the last $10.25-a-share offer “substantially undervalued” the company, it is questionable whether its position will change. 

Suggested Articles

The FDA has cleared its first duodenoscope designed to make the intricate, moving and difficult-to-clean parts in the head of the device disposable.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.